---
schema_version: "secwatch.filing_event.v1"
accession: "0001357459-26-000011"
form_type: "8-K"
ticker: "PALI"
cik: "0001357459"
company_name: "PALISADE BIO, INC."
filed_at: "2026-05-12T20:14:35+00:00"
generated_at: "2026-05-12T20:56:26.997607+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Palisade Bio Q1 2026: Cash $132.6M; R&D spend up 6.4x; PALI-2108 Phase 2 UC starts Q3 2026

## Summary
- Cash and equivalents of $132.6M at March 31, 2026, sufficient through Phase 2 UC readout (2H 2027) and CD readout (early 2028).
- R&D expense $6.4M in Q1 2026 vs $1.0M in Q1 2025 (+$5.4M) driven by PALI-2108 clinical and CMC costs.
- G&A expense $4.4M in Q1 2026 vs $1.4M in Q1 2025 (+$3.0M) on higher employee costs and professional fees.
- Completed Phase 1a/b for PALI-2108; Phase 1b FSCD cohort showed sustained exposure above IC90 and modulation of inflammatory/fibrotic pathways.
- IND for Phase 2 UC expected 2Q 2026; Phase 2 UC trial start Q3 2026; Phase 2 CD trial start Q1 2027.

## SEC filing metadata
- accession: 0001357459-26-000011
- form_type: 8-K
- ticker: PALI
- cik: 0001357459
- company_name: PALISADE BIO, INC.
- filed_at: 2026-05-12T20:14:35+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1357459/000135745926000011/0001357459-26-000011-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1357459/000135745926000011/pali-20260512.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001357459-26-000011
- JSON: https://secwatch.observer/filing/0001357459-26-000011.json
- Plain text: https://secwatch.observer/filing/0001357459-26-000011.txt

## Key facts
- Earnings Releases
  PALISADE BIO, INC. reported financial results for the first quarter ended March 31, 2026.
  - Period: the first quarter ended March 31, 2026
  - Result: reported results
  source text: On May 12, 2026, Palisade Bio, Inc. (the “Company”) issued a press release announcing its financial results for the three months ended March 31, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1357459/000135745926000011/0001357459-26-000011-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.